← All trials
NCT04920760
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 21, 2021
- Primary completion
- Nov 21, 2021
- Completion date
- Dec 19, 2021
- First posted
- Jun 10, 2021
- Last posted
- Jun 18, 2021
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shiraz UniversityLead sponsor
- Shiraz UniversityReponsible party - principal investigator
- Shiraz UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.